HomeCompareACER vs NOBL

ACER vs NOBL: Dividend Comparison 2026

ACER yields 302.98% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACER wins by $1618.31M in total portfolio value
10 years
ACER
ACER
● Live price
302.98%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1618.34M
Annual income
$981,251,733.53
Full ACER calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — ACER vs NOBL

📍 ACER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACERNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACER + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACER pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACER
Annual income on $10K today (after 15% tax)
$25,753.67/yr
After 10yr DRIP, annual income (after tax)
$834,063,973.50/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, ACER beats the other by $834,063,761.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACER + NOBL for your $10,000?

ACER: 50%NOBL: 50%
100% NOBL50/50100% ACER
Portfolio after 10yr
$809.18M
Annual income
$490,625,991.66/yr
Blended yield
60.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACER right now

ACER
Analyst Ratings
1
Strong
3
Buy
4
Hold
Consensus: Hold
Altman Z
-29.9
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACER buys
0
NOBL buys
0
No recent congressional trades found for ACER or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACERNOBL
Forward yield302.98%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1618.34M$22.9K
Annual income after 10y$981,251,733.53$249.78
Total dividends collected$1554.65M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ACER vs NOBL ($10,000, DRIP)

YearACER PortfolioACER Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$40,998$30,298.44$10,917$217.08+$30.1KACER
2$159,961$116,092.41$11,903$221.48+$148.1KACER
3$594,475$423,317.38$12,962$225.68+$581.5KACER
4$2,106,378$1,470,289.30$14,099$229.68+$2.09MACER
5$7,122,619$4,868,794.58$15,319$233.49+$7.11MACER
6$23,007,746$15,386,544.17$16,628$237.10+$22.99MACER
7$71,068,926$46,450,637.66$18,033$240.53+$71.05MACER
8$210,139,057$134,095,305.48$19,539$243.78+$210.12MACER
9$595,407,325$370,558,534.30$21,154$246.86+$595.39MACER
10$1,618,337,571$981,251,733.53$22,884$249.78+$1618.31MACER

ACER vs NOBL: Complete Analysis 2026

ACERStock

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Full ACER Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this ACER vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACER vs SCHDACER vs JEPIACER vs OACER vs KOACER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.